Table 4.
Changes in the parameters between the treatment and placebo groups at the end of the intervention.
| N 2 | Treatment 3 | Placebo 3 | WSRT 4 | FDR 5 | |
|---|---|---|---|---|---|
| Cholesterol 1 (%) | 110 | −22.5 −3.6 31.6 | −7.3 2.0 21.6 | p = 0.31 | 0.41 |
| Triglycerides 1 (%) | 110 | −32.9 −1.2 52.9 | −31.9 3.0 43.1 | p = 0.91 | 0.91 |
| AC 1 (%) | 104 | −2.7 0.0 0.9 | −4.0 −1.8 0.9 | p = 0.15 | 0.34 |
| BMI 1 (%) | 103 | −4.4 −2.0 1.2 | −3.4 −1.3 1.1 | p = 0.21 | 0.3 |
| CAP 1 (%) | 39 | −10.0 −4.0 1.4 | −4.6 5.4 15.5 | p = 0.01 | 0.05 |
| TE 1 (%) | 39 | −33.4 −7.8 1.7 | −14.8 8.6 30.5 | p = 0.04 | 0.11 |
Detailed analysis of the progression of cholesterol, triglycerides, abdominal circumference (AC), body mass index (BMI), controlled attenuation parameter (CAP), and transient elastography (TE) throughout the three-month nutritional supplementation. 1 Numbers represent percentage change at the end of the study, from the start value. 2 Number of subjects that underwent both initial and final evaluation in regard to the parameter. 3 Percent change flanked by Q1 and Q3 parental values. 4 WSRT—Wilcoxon signed-rank test. 5 False discovery rate correction for multiple testing for six variables.